Abstract 591P
Background
KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (nsqNSCLC). Tyrosine kinase inhibitors (TKIs)- sotorasib and adagrasib are approved for use in patients(pts) with KRASG12C variant. A novel TKIs- active in other KRAS variants are in development. Therefore all potentially targetable KRAS variants should be routinely tested in advanced NSCLC. The next generation sequencing (NGS) is recommended for simultaneous testing of potentially actionable biomarkers.
Methods
The study was performed as part of routine genetic diagnosis of pts with nsqNSCLC within a single institution between Jan.2019-May.2023. The material for the study consisted of tissue and cytologic samples containing no less than 20% of the tumor cells. The NGS method was used to assess the mutation status of the KRAS gene. Samples were sequenced using the FusionPlex CTL ArcherDx assay on a MiniSeq instrument (Illumina).
Results
In a group of 1468 real-world patients (pts) with advanced nsqNSCLC tested with NGS KRAS prevalence was 32,3% (474 pts). KRASG12C variant was observed in 229 pts representing 15,6% pts with nsqNSCLC and 48,3% of all KRAS mutant pts. In KRAS mutant group in cytological and tissue specimen the most common variants occurred accordingly in: Gly12Cys (50%, 48%), Gly12Asp (20%, 15%), Gly12Ala (9%, 8%), Gly12Val (14%, 15%), other variants less than 5% each (table). KRAS and other mutation coexisted in 7% (34 of 474) pts. The incidence of molecular KRAS variants diagnosed with NGS were comparable between the cytological and tissue specimen. Table: 591P
Variant | All KRAS pts N=474 (100%) | Cytology N=88 (100%) | Tissue N=386 (100%) | |||
N | % | N | % | N | % | |
Gln61His | 20 | 4,22% | 2 | 2,27% | 18 | 4,7% |
Gly12Ala | 40 | 8,44% | 8 | 9,09% | 32 | 8,3% |
Gly12Asp | 75 | 15,82% | 18 | 20,45% | 57 | 14,8% |
Gly12Cys | 229 | 48,31% | 44 | 50,00% | 185 | 47,9% |
Gly12Val | 71 | 14,98% | 12 | 13,64% | 59 | 15,3% |
Gly12Ser | 9 | 1,90% | 1 | 1,14% | 8 | 2,1% |
Gln61Leu | 6 | 1,27% | 1 | 1,14% | 5 | 1,3% |
exon2 | 8 | 1,69% | 1 | 1,14% | 7 | 1,8% |
Gln61Lys | 7 | 1,48% | 1 | 1,14% | 6 | 1,6% |
Gly12Phe | 4 | 0,84% | 0 | 0,00% | 4 | 1,0% |
Gly12Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
Lys117Asn | 1 | 0,21% | 0 | 0,00% | 1 | 0,3% |
Gln61Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
Conclusions
The NGS is feasible for diagnosis of the KRAS mutations in real-world practice. The utility of both cytological and tissue testing is high for NGS profiling with comparable prevalence of the most frequent KRAS variants.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract